enVVeno Medical (NASDAQ:NVNO) Announces Earnings Results

enVVeno Medical (NASDAQ:NVNO) posted its earnings results on Thursday. The company reported ($6.29) earnings per share for the quarter, missing the consensus estimate of ($3.27) by ($3.02), FiscalAI reports.

enVVeno Medical Price Performance

Shares of enVVeno Medical stock traded up $0.28 during trading on Thursday, hitting $7.02. 14,439 shares of the stock were exchanged, compared to its average volume of 20,460. The firm’s 50-day moving average price is $9.11 and its 200 day moving average price is $10.38. The stock has a market cap of $4.84 million, a price-to-earnings ratio of -0.36 and a beta of 1.29. enVVeno Medical has a 12-month low of $6.52 and a 12-month high of $25.90.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of enVVeno Medical in a research note on Friday, September 25th. Zacks Research upgraded shares of enVVeno Medical to a “hold” rating in a report on Tuesday, July 7th. LADENBURG THALM/SH SH raised shares of enVVeno Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. Finally, Wall Street Zen upgraded shares of enVVeno Medical to a “hold” rating in a report on Saturday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, enVVeno Medical has an average rating of “Hold”.

enVVeno Medical Company Profile

enVVeno Medical Corporation (NASDAQ:NVNO) is a late-stage medical device company focused on developing bioprosthetic, or tissue-based, treatments for venous disease. Its primary focus is chronic venous insufficiency, a condition in which damaged or absent valves allow blood to flow backward in the veins and can cause swelling, pain, skin changes and ulcers.

The company’s lead product is the VenoValve, a surgically implanted bioprosthetic valve designed to restore one-way blood flow in the deep veins of the leg.